Open | - |
Close | - |
Volume / Avg. | 0 / 770.266K |
Day Range | - - - |
52 Wk Range | 1.420 - 11.970 |
Market Cap | $163.730M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 34 |
Short Interest | 4.15% |
Days to Cover | 5.23 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Aldeyra Therapeutics (NASDAQ: ALDX) through any online brokerage.
Other companies in Aldeyra Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Graphite Bio (NASDAQ:GRPH), CytomX Therapeutics (NASDAQ:CTMX), Atossa Therapeutics (NASDAQ:ATOS) and GlycoMimetics (NASDAQ:GLYC).
The latest price target for Aldeyra Therapeutics (NASDAQ: ALDX) was reported by Citigroup on Tuesday, October 17, 2023. The analyst firm set a price target for 8.00 expecting ALDX to rise to within 12 months (a possible 187.77% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Aldeyra Therapeutics (NASDAQ: ALDX) is $2.78 last updated March 18, 2024 at 4:02 PM EDT.
There are no upcoming dividends for Aldeyra Therapeutics.
Aldeyra Therapeutics’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Aldeyra Therapeutics.
Aldeyra Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.